Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPDATE AML: Ida-FLA and VIA in Pediatric AML
NCT07059975Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by Baylor College of Medicine. Primary endpoints: Tolerability rate of Ida-FLA, Tolerability rate of VIA for IR patients and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07059975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059975.